Tag

Glp 1 Receptor Agonists

All articles tagged with #glp 1 receptor agonists

science22 days ago•25 min saved

GLP-1 diabetes drugs might curb Alzheimer's brain plaques, review finds

A systematic review of preclinical studies and two small human trials suggests GLP-1 receptor agonists (such as liraglutide, dulaglutide, exenatide, semaglutide) consistently reduce Alzheimer’s-related proteins amyloid-beta and tau in lab and animal models, indicating potential for preventive effects. However, human data are limited and do not show cognitive reversal, so larger early-intervention trials are needed to determine if these diabetes/weight-loss drugs can prevent or slow Alzheimer's progression.

via PsyPost|

#alzheimers-disease #amyloid-beta #glp-1-receptor-agonists

science1 month ago•13 min saved

Hair-loss risk linked to GLP-1 weight-loss drugs in large study

A BMJ study of about 50,000 patients finds that GLP-1 receptor agonists used for diabetes and obesity (Mounjaro, Wegovy, Ozempic) are linked to a higher risk of hair loss than other diabetes meds, with a 37% higher risk vs SGLT-2 inhibitors and 68% higher vs DPP-4 inhibitors; most hair loss is non-scarring and may relate to weight loss/caloric restriction and micronutrient changes, though regulators are reviewing safety signals; hair loss is usually not physically harmful but can affect quality of life.

via The Independent|

#alopecia #diabetes #glp-1-receptor-agonists

health1 month ago•5 min saved

New Study Flags Hair Loss Risk with GLP-1 Drugs

A BMJ study led by the University of Pennsylvania finds that GLP-1 receptor agonists used for obesity and type 2 diabetes are linked to a higher risk of non-scarring hair loss compared with SGLT-2 and DPP-4 inhibitors, though the absolute risk is small (about 7 in 1,000 per year). The researchers suggest rapid weight loss and nutritional changes as potential mechanisms and call for more research, while noting the need to weigh this potential side effect against the drugs’ benefits in shared decision-making.

via ScienceAlert|

#alopecia #bmj-study #glp-1-receptor-agonists

health1 month ago•9 min saved

GLP-1 Weight Drugs May Dampen Binge Eating Symptoms, Review Finds

A meta-analysis of 25 RCTs (n=8,069) finds GLP-1 receptor agonists used for weight loss—such as semaglutide, tirzepatide, and liraglutide—also reduce binge eating, loss-of-control eating, and emotional eating beyond weight loss, while dietary restraint tends to rise. Researchers caution that most trials had bias and limited BED-diagnosed samples, and emphasize integrating medication with psychological therapy and social support, plus addressing public-access barriers. More independently funded, long-term studies are needed to confirm clinical utility.

via Neuroscience News|

#binge-eating-disorder #glp-1-receptor-agonists #health

health1 month ago•5 min saved

Personal Trial: An Endocrinologist Takes an Oral GLP-1 to Potentially Prevent Dementia

An endocrinologist shares a personal choice to start orforglipron, an oral GLP-1, at age 48 to potentially reduce dementia risk after watching her mother’s Alzheimer’s progression. She notes no proven dementia prevention data yet, but cites brain-related mechanisms, observational signals of lower dementia rates with GLP-1s, and mixed trial results. The decision is deeply personal, balancing evolving science with family history and broader health goals, while continuing other healthy aging practices.

via Medscape|

#alzheimers-disease #dementia-prevention #glp-1-receptor-agonists

health1 month ago•9 min saved

GLP-1 Receptor Agonists: Eye Safety Generally Reassuring Despite Rare Risks

A Medscape commentary from ADA 2026 reviews eye safety of GLP-1 receptor agonists, noting rare associations with nonarteritic anterior ischemic optic neuropathy (NAION) and concerns about rapid worsening of diabetic retinopathy (EWDR). Real-world data and EMA updates suggest the overall benefits of GLP-1s outweigh these small ocular risks, but clinicians should ensure up-to-date retinal screening and advise patients to report visual changes; ongoing trials (eg, FOCUS) and mixed studies on neovascular AMD yield no definitive risk signal. Clinicians are encouraged to individualize care and monitor ocular health when initiating GLP-1 therapy.

via Medscape|

#diabetic-retinopathy #ewdr #eye-safety

health1 month ago•9 min saved

GLP-1 Drugs May Slow Metastasis in Obesity-Related Cancers, Early ASCO Data

Real-world TriNetX data presented at ASCO 2026 show GLP-1 receptor agonists used after cancer diagnosis linked to reduced metastatic progression across several obesity-related cancers, notably NSCLC, breast, colorectal, and hepatocellular carcinoma; in NSCLC, progression to stage IV was 10.0% with GLP-1 RAs vs 22.3% with DPP-4 inhibitors (HR 0.50). GLP-1 receptor expression also correlated with better overall survival, suggesting a potential class effect and the need for further study.

via The ASCO Post|

#breast-cancer #glp-1-receptor-agonists #health

health1 month ago•11 min saved

GLP-1 Weight Drugs May Lower Cancer Risk, But More Proof Is Needed

Early observational studies link GLP-1 receptor agonists—widely used for diabetes and weight loss—with a lower risk of several obesity-related cancers, including breast cancer, with a Penn Medicine study showing a 30–35% lower incidence in users; the proposed benefits may come from weight loss, reduced inflammation, improved insulin sensitivity, and lower estrogen after menopause, and possibly direct anti-cancer effects. However, these findings are not from randomized trials and GLP-1s are not FDA-approved for cancer prevention; safety concerns like medullary thyroid carcinoma warning exist, so for now cancer prevention relies on established screenings and managing metabolic health, with any future preventive use limited to high-risk patients under supervision.

via Health US News|

#breast-cancer #cancer-risk #glp-1-receptor-agonists

health2 months ago•13 min saved

Semaglutide Shows 3–5 Year Slowdown in Biological Aging in a 2025 Trial

In a 32-week, randomized trial of 108 adults with HIV-associated lipohypertrophy, weekly semaglutide reduced biological age by about 3.1 years on multiple epigenetic clocks and up to 5 years on the most sensitive ones, with DunedinPACE slowing by ~9%. The biomarker shifts correlated with reductions in inflammation and visceral fat, suggesting aging slows via metabolic effects rather than a direct anti-aging action. Limitations include population specificity and reliance on epigenetic biomarkers; broader trials are needed to determine applicability to the general population and real-world health outcomes.

via Space Daily|

#aging #epigenetic-clocks #glp-1-receptor-agonists

health-and-medicine2 months ago•5 min saved

GLP-1 Weight-Loss Drugs Trim Pounds But Also Trim Activity

A study presented at ENDO 2026 analyzed Fitbit data from NIH All of Us and found that adults with obesity who started GLP-1 medications (semaglutide or tirzepatide) lost weight but became less physically active. Average daily steps dropped from 5,047 to 4,487 and moderate-to-vigorous physical activity fell from 28 to 22 minutes per day, with the largest decreases in men and those reporting joint/muscle pain. Age, heart failure, and prior stroke did not change the trend. The researchers stress that exercise should accompany GLP-1 therapy to protect muscle and long-term health, marking the first large wearable-data study of activity in users of these drugs.

via ScienceDaily|

#endo-2026 #fitbit-data #glp-1-receptor-agonists

health2 months ago•5 min saved

GLP-1 Obesity Drugs Suppress Movement, Threatening Muscle During Weight Loss

A large real-world study using NIH All of Us and Fitbit data finds adults starting GLP-1 obesity medications reduce daily steps (5,047→4,487) and MVPA (28→22 minutes), contradicting the assumption that weight loss boosts activity. The decline risks lean muscle loss during rapid weight loss, underscoring the need to pair GLP-1 treatments with structured exercise and resistance training from the start. The analysis, drawn from 1,950 adults with 753 wearing-device users, shows the biggest drops in men and those with joint/muscle pain, while age or cardiovascular history did not shield against the trend; researchers call for integrated behavioral interventions and remote monitoring.

via Neuroscience News|

#glp-1-receptor-agonists #health #lean-muscle-mass

health3 months ago•6 min saved

Weight-Loss Drugs Show Long-Term Heart Benefits Across High-Risk Patients

A meta-analysis of 11 cardiovascular outcome trials (over 90,000 patients) finds GLP-1 receptor agonists reduce major cardiovascular events and all-cause mortality by about 13% over an average follow-up of nearly three years, with benefits seen in high-risk groups including those with or without diabetes. While GI side effects (nausea, vomiting) are more common, no significant safety signals like pancreatitis or hypoglycemia emerged. The results suggest these obesity/diabetes drugs may play a broader role in cardiovascular risk reduction and could influence clinical practice and policy.

via SciTechDaily|

#cardiovascular-disease #diabetes #glp-1-receptor-agonists

science4 months ago•6 min saved

GLP-1 Diabetes Drugs Target Alzheimer’s Pathology in Animal Studies

A systematic review of 30 preclinical studies finds GLP-1 receptor agonists (liraglutide, semaglutide, exenatide, dulaglutide) consistently reduce Alzheimer's hallmarks amyloid-beta plaques and tau tangles in animal and cell models, with liraglutide showing the strongest and most consistent effects; human data are limited and mixed so far, though some trials show preserved brain glucose metabolism and inflammatory marker changes, suggesting these drugs may help prevent dementia if used earlier rather than cure established disease.

via Neuroscience News|

#alzheimers-disease #amyloid-beta #glp-1-receptor-agonists

health4 months ago•4 min saved

GLP-1 Diabetes Drugs Linked to Higher Long-Term Cognitive Impairment Risk

A propensity-matched retrospective study of nearly 65,000 adults with type 2 diabetes found that those treated with GLP-1 receptor agonists had a higher long-term risk of durable cognitive impairment over 10 years (2.6% vs 1.3%), with a hazard ratio of 2.74. The study shows an association, not causation, and further research is needed to determine whether GLP-1 therapy contributes to cognitive decline or reflects underlying risk factors.

via MedPage Today|

#cognition #diabetes #epidemiology

health4 months ago•10 min saved

GLP-1 Weight-Loss Drugs: Is Muscle Loss Inevitable?

A Nature Reviews Endocrinology commentary reviews potential risks of GLP-1 receptor agonists used for obesity, noting concerns about accelerated muscle wasting and frailty in some patients; it explores mechanisms, aging-related vulnerability, and the need for biomarkers and careful monitoring, while acknowledging mixed evidence and the ongoing need for research to balance fat loss with muscle preservation.

via Nature|

#frailty #glp-1-receptor-agonists #health